Onconetix, Inc.

ONCO

$0.12

$-0.19 (-61.56%)

Closed

Onconetix approves 1-for-10 reverse stock split effective May 21, 2026 to cut shares to about 1.14 million, aiding Nasdaq compliance

Loading chart...

IndexN/A

Market Cap0.00B

Enterprise Value0.02B

Income$-0.01B

Sales$0.00B

EmployeesN/A

P/EN/A

P/S31.40

P/B1.62

P/C-2.64

EV/EBITDA-1.54

EV/SalesN/A

EPS (ttm)-82.80

EarningsN/A

Gross Margin77.62%

Oper. Margin-778.16%

Profit Margin-1720.98%

Volume125.96M

Shs Outstand0.00B

Change-61.56%

Dividend Est.N/A

Dividend Ex-DateN/A

Perf YTDN/A

Perf YearN/A

Perf 3YN/A

Perf 5YN/A

Perf 10YN/A

IPON/A

Yesterday08:00AMOnconetix, Inc. Announces 1-for-10 Reverse Stock Split(globenewswire.com)08:00AMRealbotix Provides Update on Nasdaq Listing(gurufocus.com)07:30AMRealbotix Provides Update on Nasdaq Listing(businesswire.com)03:03AMOnconetix (ONCO) Stock Surges Over 23% Overnight: Why Is It Moving?(feeds.benzinga.com)

Insider Trading

No insider trades found for ONCO.

Onconetix, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Biotech, Inc. and changed its name to Onconetix, Inc. in December 2023. Onconetix, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.

CEO: David Allan WhiteEmployees: 12onconetix.gcs-web.com

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$2.52M	$58.47K	N/A	N/A	N/A	N/A
Cost of Revenue	$1.47M	$1.19M	$6.75K	$4.89K	$3.06K	$573.00
Gross Profit	$1.06M	$-1.13M	$-6.75K	$-4.89K	$-3.06K	$-573.00
Gross Margin	41.80%	-1927.93%	0.00%	0.00%	0.00%	0.00%
Operating Expenses	$57.54M	$34.91M	$13.47M	$3.41M	$1.62M	$879.66K
Operating Income	$-56.49M	$-36.03M	$-13.48M	$-3.42M	$-1.62M	$-880.23K
Operating Margin	-2237.96%	-61634.47%	0.00%	0.00%	0.00%	0.00%
Net Income	$-58.69M	$-37.41M	$-13.42M	$-3.42M	$-1.60M	$-821.91K
Net Margin	-2325.21%	-63986.48%	0.00%	0.00%	0.00%	0.00%
EPS (Basic)	$-1823.25	$-87.60	$-1.09	$-0.31	$-0.14	$-0.07
EBITDA	N/A	N/A	N/A	N/A	N/A	N/A
Stock Option Compensation Expense	N/A	N/A	N/A	N/A	N/A	N/A
Price To Earnings Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Price To Sales Ratio	N/A	N/A	N/A	N/A	N/A	N/A
Shares Outstanding	N/A	N/A	N/A	N/A	N/A	N/A
Market Capitalization	N/A	N/A	N/A	N/A	N/A	N/A

Onconetix, Inc.

Insider Trading

Discover more